A profound ideological split is emerging within the burgeoning field of longevity science, catalyzed by a new, politically aggressive movement known as Vitalism. Unlike traditional gerontologists who focus on extending healthy lifespan (healthspan), the Vitalists—led by entrepreneurs Nathan Cheng and Adam Gries—espouse a far more radical objective: the total defeat of involuntary death. This isn’t just scientific aspiration; it is framed as a moral and political imperative that must supersede all other societal priorities.
The movement’s foundational philosophy is startlingly stark: life is inherently good, and therefore, death is fundamentally wrong. Speaking at the Vitalist Bay Summit in Berkeley, California, an event that blended elements of a tech conference, a political rally, and a wellness retreat, Cheng challenged attendees with the central tenet: “If you believe that life is good and there’s inherent moral value to life, it stands to reason that the ultimate logical conclusion here is that we should try to extend lifespan indefinitely.” For Vitalists, tackling aging is not merely a scientific pursuit but a “moral duty” demanding a revolutionary shift in global resource allocation.
The Branding of a Revolution
The emergence of Vitalism stems from a perceived “branding problem” within the broader life extension sector. Co-founder Adam Gries, an energetic former tech entrepreneur, argued that terms like "longevity" have been diluted by the wellness industry, often used to market unproven supplements. "Anti-aging" is associated with cosmetic clinics, while "transhumanism" is often dismissed as esoteric science fiction, encompassing goals far beyond the immediate defeat of biological decay. Vitalism was conceived as a clean slate, a singular, unapologetic focus on making death obsolete through scientific, political, and cultural upheaval.
This is not a movement content with incremental scientific breakthroughs; it aims for systemic transformation. Gries insists that for Vitalism to succeed, national budgets, regulatory policy, and cultural attitudes must align to elevate indefinite life extension to the absolute pinnacle of human endeavor. He frequently draws comparisons to the Apollo program, suggesting that if less than 1% of the US GDP could put humanity on the moon, a similar dedication to curing aging could yield monumental results in human health.
The movement is strategically organized under the Vitalism International Foundation, a nonprofit established to accelerate this mission. Beyond attracting paying members and informal followers, the Foundation actively “certifies” qualifying biotech firms—a process that requires companies to demonstrate alignment with the goal of ending aging entirely, often explicitly forbidding "apologetic narratives that accept aging or death." This formalization ensures that capital and intellectual energy are directed only toward the most aggressive, endgame-focused research.
Infiltrating the Scientific Establishment
For decades, radical longevity advocates—particularly those speaking openly of "optional death"—were marginalized by the academic mainstream. Researchers in gerontology often distanced themselves from such rhetoric, fearful that association with "immortality quests" would taint the serious molecular biology of aging. The Vitalists, however, are successfully dismantling this academic firewall.
The Vitalist Bay Summit, a three-day event exploring tools from cryonics to regulatory reform, saw a remarkable degree of collegiality from established institutions. Academics from top-tier universities, including Harvard, Stanford, and UC Berkeley, participated. Even prominent figures like Eric Verdin, director of the highly respected Buck Institute for Research on Aging, while expressing philosophical differences, acknowledged the freedom for such ideas to flourish within the broader movement.
Crucially, this influence extends into the federal government’s highest-level research agencies. Representatives from ARPA-H (Advanced Research Projects Agency for Health), the US federal agency tasked with driving breakthrough health technologies, were visibly present at Vitalist events. Mark Hamalainen, a science and engineering advisor at ARPA-H and a self-described Vitalist, views the movement as a successful rebranding of transhumanism’s less radical elements. This growing presence of self-identified Vitalists or those ideologically aligned within federal agencies, such as the Department of Health and Human Services (HHS), signals a profound shift. High-profile officials, including Jim O’Neill, Deputy Secretary of HHS, are known longevity enthusiasts, having deep ties to the radical longevity community, including past roles at organizations founded by controversial life extension pioneers like Aubrey de Grey. Gries notes this alignment, proclaiming that the current administration appears to be “the most pro-longevity administration in American history.”
The Political Strategy: Regulatory Arbitrage
The Vitalists recognize that scientific progress alone is insufficient; regulatory hurdles present the most immediate roadblock to radical life extension therapies. Their political strategy pivots on creating low-regulation zones to fast-track experimental treatments—a concept known as regulatory arbitrage.
Early ambitions centered on establishing a “longevity state” by leveraging the concept of the “network state,” a decentralized, mission-driven community proposed by figures like Balaji Srinivasan. Initial attempts included temporary settlements like Zuzalu in Montenegro and Vitalia in Próspera, a special economic zone in Honduras. These pop-up communities served as laboratories for accelerated biohacking and low-regulation governance.
However, the strategy has become more pragmatic, focusing on lobbying within the existing US political framework. The Vitalist network and allied organizations like the Alliance for Longevity Initiatives (A4LI) have successfully influenced state policy. This was most evident in Montana, which passed legislation allowing clinics to sell experimental therapies after only preliminary safety testing, bypassing traditional, lengthy efficacy trials. Similar efforts are underway in states like New Hampshire, expanding “right-to-try” laws to grant broader access to unapproved treatments.
Patri Friedman, a prominent libertarian thinker and founder of the Seasteading Institute, champions this deregulatory push, arguing that the typical "10 years and a billion dollars to pass a drug" paradigm imposed by the FDA is unacceptable to those seeking life extension. He views the regulatory delays as tantamount to "murder by omission." While the long-term goal of colonizing autonomous “seasteads” or establishing dedicated longevity states remains, the current focus is on chipping away at established regulatory oversight through legislative influence.
Targeting High-Leverage Individuals
The Vitalist revolution, Gries posits, does not require mass public consensus. Drawing a provocative, if "terrible," historical comparison to the beginnings of authoritarian movements, ARPA-H advisor Mark Hamalainen suggested: “You don’t have to convince the mainstream… Sometimes you just have to convince the right people.” Gries estimates that only 3% to 4% of society—if comprised of the right actors—could trigger the necessary societal shift.
This realization dictates a highly selective recruitment strategy focused on "high-leverage people": high-net-worth individuals ($10 million+), influential academics, policy experts, and government leaders. The goal is to funnel significant capital into longevity research and, more critically, to secure mission-aligned candidates in key governmental positions that control vast research budgets, such as those within the National Institutes of Health (NIH) or ARPA-H.
The commercial sector is responding. Companies like Shift Bioscience, which uses advanced computational biology and CRISPR to identify genes capable of cellular rejuvenation, proudly carry the "Certified Vitalist Organization" label. Daniel Ives, Shift’s co-founder and "Vitalist CEO," emphasizes that the label is necessary to distinguish their serious molecular biology from the “spurious claims” of the mainstream wellness industry, ensuring they attract the most “hardcore” investors and collaborators. Similarly, AgelessRx, a telehealth provider selling purported longevity drugs, boasts substantial annual revenue, seeing every customer interaction as an opportunity to "evangelize" radical life extension.
The Ethical Friction and Future Trajectories
The rising influence of Vitalism brings sharp ethical debates to the forefront of technology and medicine. The rapid push for deregulation, exemplified by the Montana model, raises serious concerns among bioethicists regarding patient safety and oversight. Unproven, experimental treatments, some potentially dangerous, are entering the market with minimal regulatory scrutiny, driven by a philosophy that prioritizes immediate access over traditional clinical validation.
Beyond the immediate regulatory risks, the Vitalist movement challenges deeply held cultural and moral beliefs about the human condition. Philosophers and ethicists argue that the quest to eradicate death misunderstands its cultural significance. Sergio Imparato, a moral philosopher at Harvard, argues that death provides crucial moral meaning; the finitude of life is precisely what lends value and urgency to human actions. Alberto Giubilini of Oxford University agrees, noting that human societies, cultures, and psychology are fundamentally structured around the process of coping with mortality. The Vitalist attempt to fundamentally change what it means to be human, they argue, demands a consensus that transcends a small group of wealthy, ideologically driven advocates.
Despite these profound ethical counter-arguments, the movement exhibits a high degree of organizational discipline. Gries advises adherents to avoid language that sounds overtly religious or sensationalist—terms like "eternity," "radical," or "forever"—in a calculated effort to manage public perception and reduce stigma.
The impact of Vitalism is already visible in the mainstream. The highly regarded Aging Research and Drug Discovery (ARDD) conference in Copenhagen now features sponsorship from Vitalist-aligned ventures. Furthermore, the attendance of key federal figures at events like the A4LI summit in Washington, D.C., and the subsequent congressional briefings, underscores how far the conversation has shifted. While political leaders like Representative Gus Bilirakis (R-FL) and figures like former TV doctor Mehmet Oz (who now heads the Centers for Medicare and Medicaid Services) frame longevity in terms of reducing chronic disease and promoting “Make America Healthy Again,” their embrace of aging science provides a crucial platform for the more radical elements in the audience.
Whether or not the Vitalists achieve their ultimate goal of indefinite life extension, their influence is undeniable. By aggressively organizing wealthy patrons, infiltrating policy-making circles, and creating new, ideologically focused biotech organizations, they are ensuring that the most radical forms of life extension remain a primary, politically backed trajectory for future scientific investment and regulatory reform. The revolution, it appears, is no longer confined to the lab; it is being fought in the halls of state legislatures and federal agencies.